Thryv Therapeutics

We will relentlessly pursue treatments targeting SGK1 to enable people to live their absolute best lives.

Without Limits.

Now enrolling! Wave II, a clinical research study for people living with Long QT Syndrome Type 2 (LQTS2).

Learn more here.

Our Focus:

Thryv Therapeutics is pioneering a precision medicine approach to treat indications including Congenital Long QT Syndrome (LQTS), atrial fibrillation and heart failure with potent and selective inhibitors of Serum Glucocorticoid inducible Kinase (SGK1).

Explore

Breaking Barriers:

Press Releases

Thryv Therapeutics Launches Pivotal Wave II Phase 2/3 Study in Long QT Syndrome Type 2

Thryv Therapeutics Launches Pivotal Wave II Phase 2/3 Study in Long QT Syndrome Type 2

Thryv Therapeutics Announces Positive Phase 1 Results of THRV-1268 in Obese Participants

Thryv Therapeutics Announces Positive Phase 1 Results of THRV-1268 in Obese Participants

Thryv Therapeutics Strengthens Senior Leadership Team with Appointment of Matt Killeen, PhD, as Chief Business Officer

Thryv Therapeutics Strengthens Senior Leadership Team with Appointment of Matt Killeen, PhD, as Chief Business Officer

Thryv Therapeutics Launches myQTwave: A First-of-its-Kind Remote Study Enabling People with Long QT Syndrome to Join Cardiac Research

Thryv Therapeutics Launches myQTwave: A First-of-its-Kind Remote Study Enabling People with Long QT Syndrome to Join Cardiac Research

Amy Rudolph, PhD, Joins Thryv Therapeutics’ Board of Directors to Support Portfolio Progression into Heart Failure

Amy Rudolph, PhD, Joins Thryv Therapeutics’ Board of Directors to Support Portfolio Progression into Heart Failure

Thryv Therapeutics to Present at the 2025 American Heart Association Scientific Sessions in New Orleans, LA

Thryv Therapeutics to Present at the 2025 American Heart Association Scientific Sessions in New Orleans, LA

Thryv Therapeutics to Participate in Upcoming 2025 Healthcare Investor Conferences

Thryv Therapeutics to Participate in Upcoming 2025 Healthcare Investor Conferences

Thryv Therapeutics Announces FDA IND Clearance of THRV-1268 for Long QT Syndrome

Thryv Therapeutics Announces FDA IND Clearance of THRV-1268 for Long QT Syndrome

Thryv Therapeutics Receives FDA IND Clearance of THRV-1268 for Heart Failure and Atrial Fibrillation and Presents SGK1 Inhibition Results Combined with Jardiance in Pressure Overload Model at ESC 2025

Thryv Therapeutics Receives FDA IND Clearance of THRV-1268 for Heart Failure and Atrial Fibrillation and Presents SGK1 Inhibition Results Combined with Jardiance in Pressure Overload Model at ESC 2025

Thryv Therapeutics to Present at the 2025 European Society of Cardiology Congress in Madrid, Spain

Thryv Therapeutics to Present at the 2025 European Society of Cardiology Congress in Madrid, Spain

Thryv Therapeutics to Share Recent Clinical Results and Participate in Upcoming Healthcare Investor Conferences

Thryv Therapeutics to Share Recent Clinical Results and Participate in Upcoming Healthcare Investor Conferences

Thryv Therapeutics to Present at the 2025 Heart Rhythm Society Annual Meeting in San Diego, CA

Thryv Therapeutics to Present at the 2025 Heart Rhythm Society Annual Meeting in San Diego, CA

Thryv Therapeutics to Participate in the 2025 Piper Sandler Virtual Cardio Day

Thryv Therapeutics to Participate in the 2025 Piper Sandler Virtual Cardio Day

Thryv Therapeutics to Participate in the 2025 Leerink Partners Global Healthcare Conference in Miami, FL

Thryv Therapeutics to Participate in the 2025 Leerink Partners Global Healthcare Conference in Miami, FL

Thryv Therapeutics to Attend the 2025 J.P. Morgan Healthcare Conference in San Francisco

Thryv Therapeutics to Attend the 2025 J.P. Morgan Healthcare Conference in San Francisco

Thryv Therapeutics Announces the Appointment of Esteemed Executive Leader Amy Sehnert, MD, as Chief Medical Officer

Thryv Therapeutics Announces the Appointment of Esteemed Executive Leader Amy Sehnert, MD, as Chief Medical Officer

Thryv Therapeutics Announces Completion of Phase 1 Dosing of its Second Novel SGK1 Inhibitor THRV-1268 - Future Studies in Heart Failure and Atrial Fibrillation to Commence in 2025

Thryv Therapeutics Announces Completion of Phase 1 Dosing of its Second Novel SGK1 Inhibitor THRV-1268 - Future Studies in Heart Failure and Atrial Fibrillation to Commence in 2025

Thryv Therapeutics Announces Participation in Four Major Upcoming Investor Conferences

Thryv Therapeutics Announces Participation in Four Major Upcoming Investor Conferences

Thryv Therapeutics to Sponsor and Participate in the 2024 International SADS Foundation Family Conference in Chicago

Thryv Therapeutics to Sponsor and Participate in the 2024 International SADS Foundation Family Conference in Chicago

Thryv Therapeutics Announces Four Abstracts Accepted for AHA 2024 Annual Scientific Sessions

Thryv Therapeutics Announces Four Abstracts Accepted for AHA 2024 Annual Scientific Sessions

Thryv Therapeutics Receives Positive Top-Line Results from Wave I Part 2 Clinical Study in Long QT Syndrome Type 2 and Type 3 Patients

Thryv Therapeutics Receives Positive Top-Line Results from Wave I Part 2 Clinical Study in Long QT Syndrome Type 2 and Type 3 Patients

Isla Hutton

Long QT Type 3

We gain momentum everyday in our relentless pursuit of a treatment for Long QT Syndrome — In memory of Isla.

Isla Hutton

Isla Hutton

Isla Hutton

Isla Hutton

Isla Hutton

Isla Hutton

Isla Hutton

Isla Hutton

Isla Hutton

Isla Hutton

Isla Hutton

Together We Thryv

The enthusiasm of our investors is a reflection of breakthrough science, hard work and the dedication of our scientists, founders and collaborators.

Together we share a vision to transform the lives of people with life-threatening conditions.

Amplitude Ventures (Copy)

The Fonds de solidarité FTQ (Copy)

Lumira Ventures (Copy)

Amzak Health (Copy)

Alexandria Venture Investments (Copy)

adMare BioInnovations (Copy)

Follow our journey

Grateful today and every day for the incredible community that supports and strengthens our work in cardiac care. 💛

To the patients, families, advocates, clinicians, scientists, and partners who inspire us—thank you.
Wishing you all a warm, p

Three years ago, the world lost a bright little girl named Isla Hutton to Long QT Syndrome (LQT3). ❤️

At Thryv, Isla’s story — and the love and strength of her father, Dave Hutton (@thelongcutielegacy), who continues to advocate for fami

With FDA IND clearance and backing from leading life sciences investors, Thryv Therapeutics is advancing THRV-1268, our lead SGK1 inhibitor, into Phase 2/3 development for Long QT Syndrome. This combination of regulatory momentum and financing suppor

🚀 Driving science forward at #ESC2025.

Last week, Thryv Therapeutics showcased new preclinical data from a pressure overload (TAC) heart failure model, demonstrating that our lead SGK1 inhibitor, THRV-1268—alone and combined with Jardiance (e

📣 We’re headed to #ESCCongress this weekend! Thryv Therapeutics is proud to announce that we’ll be presenting compelling new preclinical results on our lead SGK1 inhibitor, THRV-1268, at the 2025 European Society of Cardiology Congress i

🔬 It all starts in the lab.
Delphine, Kayluz, and Julie are part of the team powering our research forward. From bench to breakthrough, they’re working behind the scenes to better understand SGK1 inhibition and its potential to transform the t

🌍 Today on International Clinical Trials Day, we shine a light on the importance of clinical research—especially in the fight against rare diseases, where each trial offers a critical opportunity for progress and hope.

From the patients who

Hypertension is more than high blood pressure—it’s a global health crisis.

It occurs when the force of blood pushing against the walls of your arteries is consistently too high, putting extra strain on your heart and blood vessels. Over

Thryv Therapeutics to share latest clinical results of SGK1 inhibition in patients with Long QT Syndrome Types 2 & 3 at the upcoming RBC and Jefferies Healthcare Conferences in NYC.

Join us May 20–21 (RBC) and June 3–5 (Jefferies) to

On International Nurses Day, we honor the nurses whose expertise, compassion, and leadership drive better patient outcomes — and stronger healthcare systems around the world.

This year’s theme, “Our Nurses. Our Future. Caring for n

May is National Stroke Awareness Month — and at Thryv, we recognize the importance.

Stroke is the most serious and life-threatening complication of atrial fibrillation, increasing risk by fivefold. Our work is focused on understanding and addr

📣 Going to Heart Rhythm 2025? Join us this Sunday for an oral presentation at #HRS2025.

🗓️ Sunday, April 27 | 8:00–9:00 AM PT
📍 Oral Abstract Hub 4 – Sails Pavilion, SDCC
👨&zwj;⚕️ Presenter: Dr. Philip Sager
🧬 Title: SGK-1 Inhibitio

📣 We’re headed to #HRS2025! Thryv Therapeutics is proud to announce that we’ll be presenting new clinical data at the 2025 Heart Rhythm Society Annual Meeting.

Join us on Sunday, April 27 as we share findings from our Wave I, Part 2 stu

Science knows no borders! We're proud to have a team made up of scientists, researchers, and innovators from both sides of the border—and around the world! We stand in support of our colleagues, mentors and the thousands of passionate scientist

Thryv Therapeutics is looking forward to participating in the 2025 Piper Sandler Virtual Cardio Day on April 1.

Our leadership team will sit for a fireside chat from 11:30–11:55 a.m. ET, discussing key insights into our latest advancements in

Thank you for joining us this Heart Month as we raised awareness about heart health! We appreciate your engagement and hope you learned something new about Long QT Syndrome, atrial fibrillation, heart failure, and the role of SGK1 in cardiac health.

Heart failure (HF) affects millions, yet treatment options remain limited—especially for HFpEF (pronounced "heff-peff"), a condition where the heart struggles to relax and fill properly.

Two Types of Heart Failure
🔹 HFpEF ("h

This Week, We’re Talking About Atrial Fibrillation (AFib) 💓 #HeartMonth

AFib is the most common heart rhythm disorder, affecting over 5M Americans today and 200K Canadians. It occurs when the heart’s upper chambers beat irregularly, dis

This Week, We’re Talking About Heart Failure 🫀 #HeartMonth

Heart failure (HF) is a serious condition that affects over 6 million Americans and is the leading cause of hospitalization for people over 65. In Canada, approximately 750,000 peopl